Invivyd (IVVD) said Monday that the US Food and Drug Administration rejected its request to expand the existing emergency use authorization for Pemgarda to include treatment of mild-to-moderate Covid-19 in immunocompromised adults and adolescents.
The drug, also called pemivibart, is already being used as a preventative measure for some immunocompromised patients who are not currently sick with Covid-19, the company said.
Invivyd said its application for pemivibart as a Covid-19 treatment option was not considered in its current financial guidance and that it plans to publicly share detailed data and regulatory correspondence regarding pemivibart in comparison with other drugs.
Shares of the company were down more than 34% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.